HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion
chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and toripalimab in
patients with advanced hepatocellular carcinoma (HCC)